International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	CLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MODERN HEMATOLOGY: DIAGNOSTIC AND PROGNOSTIC PERSPECTIVES
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5461
RECEIVED	23 February 2026
ACCEPTED	16 June 2026
PUBLISHED	19 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

CLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MODERN HEMATOLOGY: DIAGNOSTIC AND PROGNOSTIC PERSPECTIVES

Joanna Strzelczyk *(Corresponding Author, Email: strzelczykjoanna@tlen.pl)*
Nicolaus Copernicus Provincial Multispecialty Center for Oncology and Traumatology in Łódź, Poland
ORCID ID: 0009-0006-8212-9431

Izabela Zuzanna Stranz
Ludwik Rydygier Provincial Hospital in Toruń, Poland
ORCID ID: 0009-0002-3689-0132

Anna Łęczycka
Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Gdańsk, Poland
ORCID ID: 0009-0004-9068-5222

Kinga Haduch
University Hospital in Kraków, Poland
ORCID ID: 0009-0004-4853-9395

Zuzanna Michalska
Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia Mazury Oncology Centre in Olsztyn, Poland
ORCID ID: 0009-0005-8775-102X

Nicole Aleksandra Ordyczyńska-Mardyła
District Hospital in Chrzanów, Poland
ORCID ID: 0009-0007-1502-8291

Aleksandra Stańczyk
Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Poland
ORCID ID: 0009-0000-2356-7841

Olga Chorąży
Independent Public Healthcare Center Myślenice, Poland
ORCID ID: 0009-0001-3094-2299

Amelia Kędziora
University of Warmia and Mazury in Olsztyn, Poland
ORCID ID: 0009-0001-8883-4370

Iga Suchta
District Hospital in Proszowice, Poland
ORCID ID: 0009-0005-5837-5790

ABSTRACT

Artificial intelligence (AI) has recently emerged as an important tool supporting diagnostics and clinical decision-making across multiple fields of medicine, including hematology. Rapid advances in machine learning algorithms and computational data analysis have enabled the processing and interpretation of complex biomedical datasets derived from laboratory diagnostics, medical imaging, and molecular studies [1,2]. These developments are particularly relevant in hematology, where the interpretation of large volumes of morphological, immunophenotypic, and genetic data plays a crucial role in disease diagnosis and monitoring.

In hematological practice, artificial intelligence has demonstrated promising applications in the automated analysis of peripheral blood smears and bone marrow aspirates, as well as in the interpretation of flow cytometry data and molecular diagnostic results [3,4]. Several studies have shown that AI-based systems can achieve high levels of sensitivity and specificity in the detection of abnormal cellular populations, including leukemic blasts, potentially improving diagnostic accuracy and reducing the time required for laboratory evaluation [5].

Despite these promising developments, the clinical implementation of artificial intelligence in hematology remains associated with several challenges, including the need for large, high-quality training datasets, external validation across different patient populations, and integration with existing laboratory information systems [6].

The aim of this article is to review the current state of knowledge regarding the use of artificial intelligence in hematology, with particular emphasis on its applications in laboratory diagnostics, microscopic image analysis, and prognostic modeling in hematological diseases.

KEYWORDS

Hematology, Artificial Intelligence, Blood Cell Analysis, Bone Marrow Analysis

CITATION

Joanna Strzelczyk, Izabela Zuzanna Stranz, Anna Łęczycka, Kinga Haduch, Zuzanna Michalska, Nicole Aleksandra Ordyczyńska-Mardyła, Aleksandra Stańczyk, Olga Chorąży, Amelia Kędziora, Iga Suchta. (2026) Clinical Applications of Artificial Intelligence in Modern Hematology: Diagnostic and Prognostic Perspectives. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5461

1. Introduction

Hematological disorders represent a significant global health burden and encompass a broad spectrum of benign and malignant diseases affecting the blood and hematopoietic system. Among these conditions, hematological malignancies—including leukemias, lymphomas, and multiple myeloma—are characterized by considerable biological heterogeneity and complex clinical behavior [7]. Accurate and timely diagnosis is therefore essential for the appropriate selection of therapeutic strategies and for determining patient prognosis.

Modern hematology relies on the integration of multiple diagnostic modalities. These include conventional laboratory techniques such as complete blood count analysis and microscopic examination of peripheral blood smears, as well as advanced diagnostic methods including flow cytometry, cytogenetics, and molecular genetic testing [8,9]. The combination of these diagnostic approaches allows clinicians to obtain a comprehensive understanding of disease biology and to identify specific pathological cell populations that may guide treatment decisions.

Despite substantial technological progress, many aspects of hematological diagnostics remain dependent on expert interpretation. Microscopic examination of peripheral blood and bone marrow specimens continues to play a fundamental role in the diagnosis of hematological diseases. However, manual morphological assessment can be time-consuming and may be associated with a degree of inter-observer variability, particularly in cases involving subtle morphological abnormalities or rare cell populations [10]. Similarly, the interpretation of complex datasets generated by flow cytometry and molecular diagnostics requires considerable expertise and experience.

The rapid expansion of digital technologies in laboratory medicine has resulted in the generation of increasingly large and complex diagnostic datasets. This trend has created new opportunities for the application

of artificial intelligence techniques capable of identifying patterns within large volumes of biomedical data [11]. Machine learning algorithms, including deep learning models, have demonstrated significant potential in image recognition and pattern detection tasks, making them particularly suitable for applications in laboratory hematology.

In recent years, artificial intelligence has been increasingly explored as a supportive tool in hematological diagnostics. AI-based systems have shown promising results in automated blood cell classification, detection of leukemic blasts, and interpretation of multidimensional data obtained from flow cytometry and molecular testing [3,4,12]. By assisting clinicians in the analysis of complex diagnostic information, these technologies may contribute to improved diagnostic accuracy and more efficient laboratory workflows.

However, despite the growing number of studies demonstrating the potential of artificial intelligence in hematology, several challenges remain before these tools can be widely implemented in routine clinical practice. These challenges include the need for robust model validation, standardization of training datasets, and the development of transparent algorithms that can be reliably integrated into existing clinical workflows [6].

The aim of this review is to summarize current knowledge regarding the clinical applications of artificial intelligence in hematology. Particular attention is given to its role in laboratory diagnostics, including morphological analysis of blood and bone marrow specimens, interpretation of flow cytometry data, and the development of prognostic models that may support clinical decision-making in hematological diseases.

2. Methodology

This study was conducted as a structured narrative review of the current literature on the applications of artificial intelligence in hematology, with a particular focus on diagnostic and prognostic use cases. The aim was to identify, analyze, and synthesize recent scientific evidence regarding the implementation of machine learning and deep learning techniques in laboratory hematology.

A literature search was conducted using major scientific databases, including PubMed using combinations of keywords related to artificial intelligence and hematology.

Studies were included if they focused on the clinical or experimental application of artificial intelligence in hematology, particularly in areas such as morphological analysis of peripheral blood and bone marrow, interpretation of flow cytometry data, detection of minimal residual disease, and prognostic prediction in hematologic malignancies. Both original research articles and high-quality review papers were considered. Studies were excluded if they did not involve AI-based methods, lacked clinical relevance, or were limited to single case reports.

3. Results

3.1 Current Diagnostic Approaches in Hematology

3.1.1 Peripheral Blood Morphology

Examination of peripheral blood morphology remains a fundamental component of hematological diagnostics. Despite the rapid development of molecular and immunophenotypic techniques, microscopic assessment of blood smears continues to provide essential information regarding the presence of abnormal cell populations, including immature precursors, dysplastic cells, and circulating blasts [9]. In many clinical situations, the peripheral blood smear represents the first indication of an underlying hematologic disorder and may guide further diagnostic investigations.

The evaluation of blood smear morphology typically involves the assessment of erythrocytes, leukocytes, and platelets with respect to their size, shape, staining characteristics, and maturation stage. Morphological abnormalities such as anisocytosis, poikilocytosis, or the presence of atypical leukocytes may indicate a wide spectrum of hematologic conditions ranging from nutritional deficiencies and hemolytic disorders to malignant diseases such as acute leukemias or myelodysplastic syndromes [9].

In the context of hematologic malignancies, microscopic analysis of peripheral blood plays a particularly important role in the detection of blast cells and other abnormal hematopoietic elements. The identification of circulating blasts often raises suspicion for acute leukemia and typically prompts immediate diagnostic confirmation using bone marrow examination, immunophenotyping, and cytogenetic analysis [8]. Consequently, the accuracy of morphological evaluation can have direct implications for the timeliness of diagnosis and initiation of therapy.

However, manual microscopic evaluation of blood smears presents several limitations. The process is inherently time-consuming and requires substantial expertise from trained hematologists or laboratory

specialists. Furthermore, morphological interpretation may be influenced by observer variability, particularly in cases involving subtle cytological abnormalities or rare cell populations [10]. Differences in training and experience between observers can lead to inconsistencies in diagnostic interpretation, which may affect clinical decision-making.

In recent years, advances in digital microscopy and image analysis have created new opportunities for improving the evaluation of blood cell morphology. High-resolution digital slide scanners now allow blood smear images to be captured, stored, and analyzed using computational methods [6]. These developments have paved the way for the application of artificial intelligence algorithms capable of automatically identifying and classifying blood cells based on morphological features.

Several studies have demonstrated that deep learning models trained on large datasets of blood smear images can achieve diagnostic performance comparable to that of experienced hematologists in tasks such as leukocyte classification and blast detection [5]. These technologies have the potential to support laboratory professionals by providing rapid pre-screening of samples, highlighting suspicious cells, and reducing the workload associated with routine morphological analysis.

Nevertheless, despite these promising developments, the integration of automated image analysis systems into routine hematology diagnostics remains limited. Challenges include the need for large annotated datasets, standardization of image acquisition procedures, and validation of algorithm performance across different laboratories and patient populations. As a result, artificial intelligence is currently considered a supportive tool rather than a replacement for expert morphological evaluation.

3.1.2 Flow Cytometry

Flow cytometry represents one of the most important diagnostic tools in modern hematology and plays a central role in the identification, classification, and monitoring of hematologic malignancies. This technique enables the simultaneous analysis of multiple cellular parameters by measuring the expression of specific surface and intracellular markers using fluorescently labeled antibodies [11]. As a result, flow cytometry allows the detailed characterization of immunophenotypic profiles of hematopoietic cells and the identification of abnormal cell populations that may indicate malignant transformation.

In clinical practice, flow cytometry is widely used for the diagnosis and classification of acute leukemias, lymphomas, and plasma cell disorders. By analyzing the expression patterns of lineage-specific antigens, clinicians can distinguish between different subtypes of leukemia and identify aberrant immunophenotypic features that are characteristic of particular disease entities [8]. Furthermore, flow cytometry plays a critical role in the detection of minimal residual disease (MRD), which refers to the presence of small numbers of malignant cells that remain after treatment and may eventually lead to disease relapse.

Despite its high diagnostic value, the interpretation of flow cytometry data presents several challenges. Modern multiparameter flow cytometry generates highly complex datasets containing measurements from thousands to millions of individual cells across multiple fluorescence channels. The analysis of such high-dimensional data typically involves manual gating strategies in which specific cell populations are identified based on their antigen expression patterns. However, manual gating is time-consuming and may introduce variability between laboratories and individual analysts [30].

Recent advances in computational analysis have introduced automated and semi-automated approaches for the interpretation of flow cytometry data. Machine learning algorithms can analyze multidimensional datasets and identify complex patterns that may not be easily detectable through traditional gating strategies [26]. In particular, unsupervised clustering and dimensionality reduction techniques have been applied to classify cellular populations and detect abnormal immunophenotypic signatures associated with hematologic malignancies [32].

Several studies have demonstrated that artificial intelligence–based approaches can support the detection of minimal residual disease and improve the accuracy of disease classification using flow cytometry data [21,23]. These systems are capable of processing large datasets rapidly and may assist clinicians in identifying subtle immunophenotypic abnormalities that could otherwise be overlooked during manual analysis.

Nevertheless, despite these promising developments, the integration of artificial intelligence into routine flow cytometry diagnostics remains an evolving field. Challenges include the need for standardized datasets, reproducibility of results across different laboratories, and the development of interpretable models that can be reliably integrated into clinical workflows. Consequently, AI-based tools are currently considered complementary methods that support, rather than replace, expert interpretation of flow cytometric data.

3.1.3 Molecular Diagnostics

Molecular diagnostics has become an integral component of modern hematology, significantly improving the accuracy of disease classification, risk stratification, and treatment monitoring. Advances in molecular biology have enabled the identification of numerous genetic alterations associated with hematologic malignancies, including chromosomal translocations, gene mutations, and epigenetic modifications that influence disease pathogenesis and progression [8].

One of the most well-known examples of molecular diagnostics in hematology is the detection of the BCR-ABL1 fusion gene in chronic myeloid leukemia (CML), which results from the t(9;22)(q34;q11) chromosomal translocation, commonly known as the Philadelphia chromosome. Identification of this molecular abnormality not only confirms the diagnosis but also has direct therapeutic implications, as patients with CML benefit from targeted therapy using tyrosine kinase inhibitors [8]. Similarly, mutations in genes such as *JAK2*, *CALR*, and *MPL* are frequently detected in myeloproliferative neoplasms and provide important diagnostic and prognostic information.

In acute leukemias, molecular analysis plays a crucial role in identifying prognostically significant mutations such as *FLT3*, *NPM1*, and *CEBPA*, which may influence both treatment decisions and risk stratification [8]. These genetic markers are increasingly incorporated into modern classification systems for hematologic malignancies and contribute to a more precise understanding of disease biology.

The rapid development of next-generation sequencing (NGS) technologies has further expanded the role of molecular diagnostics in hematology. NGS allows the simultaneous analysis of multiple genes and enables comprehensive genomic profiling of hematologic cancers. As a result, clinicians are able to detect complex mutational patterns and identify molecular signatures associated with disease progression or resistance to therapy.

However, the increasing availability of genomic data also presents new analytical challenges. The interpretation of large-scale sequencing datasets requires advanced computational methods capable of identifying clinically relevant genetic alterations among numerous variants of uncertain significance. In this context, artificial intelligence and machine learning techniques are increasingly being explored as potential tools for analyzing complex genomic datasets and supporting clinical decision-making in hematologic malignancies [12].

3.1.4 Limitations of Current Diagnostic Methods

Despite significant advances in hematological diagnostics, current diagnostic approaches still present several limitations that may affect the efficiency and consistency of clinical evaluation. While methods such as microscopic examination, flow cytometry, and molecular diagnostics provide valuable information, their interpretation often relies heavily on expert knowledge and manual analysis. This reliance on human expertise may introduce variability in diagnostic interpretation, particularly in complex cases involving subtle morphological or immunophenotypic abnormalities [10].

Microscopic evaluation of peripheral blood smears and bone marrow aspirates remains a cornerstone of hematologic diagnosis; however, this process is inherently labor-intensive and time-consuming. The identification of rare or atypical cell populations requires careful examination of large numbers of cells, which may increase the risk of diagnostic oversight, especially in high-volume laboratory settings. In addition, inter-observer variability among laboratory specialists may lead to differences in interpretation, potentially influencing diagnostic conclusions and clinical management.

Similarly, modern multiparameter flow cytometry generates highly complex datasets that require detailed analysis to identify abnormal cellular populations. Although manual gating strategies remain widely used, they may be affected by subjective decision-making and inconsistencies between laboratories. As the number of measurable parameters continues to increase, the interpretation of multidimensional flow cytometry data becomes progressively more challenging [30].

Molecular diagnostic techniques, particularly next-generation sequencing, have also introduced new complexities into hematological diagnostics. The ability to detect large numbers of genetic variants simultaneously has significantly improved the understanding of disease biology. However, distinguishing clinically relevant mutations from benign variants requires sophisticated analytical tools and extensive bioinformatic support.

Taken together, these challenges highlight the growing need for computational approaches capable of supporting the analysis of large and complex diagnostic datasets. Artificial intelligence and machine learning techniques have therefore emerged as promising tools that may assist clinicians in integrating morphological, immunophenotypic, and molecular information, ultimately improving diagnostic accuracy and efficiency in hematology.

3.2 Artificial Intelligence in Morphological Analysis of Blood and Bone Marrow

3.2.1 Artificial Intelligence in Peripheral Blood Smear Analysis

The application of artificial intelligence in the analysis of peripheral blood smears has emerged as one of the most promising developments in laboratory hematology. Advances in digital microscopy and computational image analysis have enabled the development of automated systems capable of identifying and classifying blood cells based on their morphological characteristics. These systems aim to assist laboratory specialists by improving the efficiency and consistency of morphological evaluation.

One of the key technological developments enabling these applications is the use of deep learning algorithms, particularly convolutional neural networks (CNNs), which are well suited for image recognition tasks. CNN-based models can analyze large numbers of digital blood smear images and learn to recognize complex morphological patterns associated with different blood cell types. As a result, these systems are capable of automatically distinguishing between erythrocytes, leukocytes, and platelets, as well as identifying abnormal cell populations that may indicate hematologic disease [5].

In recent years, several studies have demonstrated that deep learning models can achieve diagnostic performance comparable to that of experienced hematologists in specific classification tasks. For example, convolutional neural networks trained on large datasets of peripheral blood smear images have shown high accuracy in leukocyte classification and blast detection, which are critical steps in the diagnosis of acute leukemias [5]. Automated systems can rapidly screen thousands of cells within a digital slide and highlight suspicious morphological features that may warrant further expert evaluation.

Beyond basic cell classification, artificial intelligence algorithms have also been applied to the detection of subtle morphological abnormalities that may be difficult to recognize during routine manual examination. These include dysplastic changes in myelodysplastic syndromes, atypical lymphocytes in viral infections, and abnormal precursor cells in leukemic conditions. By identifying such features early, AI-based systems may assist clinicians in recognizing pathological patterns that might otherwise remain undetected.

Another advantage of AI-driven image analysis is its ability to standardize morphological evaluation across different laboratories. Traditional microscopic analysis may be influenced by variations in observer experience, slide preparation, or staining quality. Automated systems, once properly trained and validated, may reduce such variability by applying consistent analytical criteria to all analyzed samples. This standardization may contribute to improved reproducibility of laboratory findings and facilitate collaborative research involving multicenter datasets.

Despite these promising capabilities, several challenges remain before artificial intelligence can be widely integrated into routine morphological diagnostics. The development of robust algorithms requires access to large annotated image datasets that accurately represent the diversity of hematologic conditions encountered in clinical practice. In addition, differences in staining techniques, microscope settings, and image acquisition protocols may influence algorithm performance and limit generalizability across institutions.

For these reasons, most experts currently view artificial intelligence as a supportive technology rather than a replacement for expert morphological assessment. When integrated appropriately into laboratory workflows, AI-based image analysis systems may serve as valuable decision-support tools that assist hematologists in detecting abnormal cellular populations and prioritizing cases that require detailed expert review.

3.2.2 Artificial Intelligence in Bone Marrow Morphology

Bone marrow examination remains a cornerstone of hematologic diagnostics and plays a crucial role in the evaluation of many malignant and non-malignant disorders of the hematopoietic system. Morphological analysis of bone marrow aspirate smears provides essential information regarding cellular composition, maturation patterns, and the presence of abnormal hematopoietic precursors. In particular, bone marrow morphology is fundamental for the diagnosis and classification of acute leukemias, myelodysplastic syndromes, and various myeloproliferative neoplasms [8].

Traditionally, bone marrow evaluation relies on manual microscopic examination performed by experienced hematologists or hematopathologists. During this process, specialists assess hundreds of hematopoietic cells to determine lineage distribution and detect abnormal cellular populations. However, this approach is time-intensive and may be affected by inter-observer variability, particularly in cases involving subtle dysplastic features or rare malignant cells. As a result, efforts have been made to develop automated methods that can assist in the analysis of bone marrow morphology.

Recent advances in digital pathology and artificial intelligence have enabled the development of computational systems capable of analyzing bone marrow aspirate images. Similar to peripheral blood smear

analysis, many of these systems rely on deep learning algorithms, particularly convolutional neural networks, which are highly effective in image recognition tasks. These models can be trained to recognize morphological characteristics of hematopoietic cells and classify them into distinct developmental stages or pathological categories.

Several studies have demonstrated the potential of AI-based systems to automatically identify and classify bone marrow cells with high accuracy. Deep learning algorithms trained on large annotated datasets of bone marrow images have shown promising results in distinguishing between normal hematopoietic cells and abnormal populations associated with diseases such as acute myeloid leukemia or myelodysplastic syndromes [13,14]. In addition to basic cell classification, AI models have also been applied to detect subtle morphological abnormalities that may be difficult to identify during manual examination.

Artificial intelligence may also facilitate the quantitative analysis of bone marrow samples. Automated systems can rapidly evaluate thousands of cells and generate detailed reports describing cellular distributions and morphological patterns. Such capabilities may support clinicians in establishing more objective diagnostic criteria and improve the reproducibility of morphological assessments across different institutions.

Despite these promising developments, several challenges remain before AI-driven bone marrow analysis can be widely implemented in clinical practice. High-quality annotated datasets are required to train robust models, and the diversity of bone marrow morphology across different diseases and patient populations may complicate algorithm generalization. Furthermore, variations in staining techniques, slide preparation, and image acquisition may influence model performance. Consequently, most experts currently consider AI-based bone marrow analysis as a complementary tool designed to assist hematopathologists rather than replace expert morphological evaluation.

3.2.3 Diagnostic Performance of Artificial Intelligence Systems

The evaluation of diagnostic performance represents a critical step in assessing the clinical utility of artificial intelligence systems in hematology. As AI-based tools are increasingly proposed as supportive instruments in laboratory diagnostics, their effectiveness must be carefully compared with established diagnostic approaches, particularly expert morphological assessment performed by trained hematologists or hematopathologists.

In the context of peripheral blood smear analysis, several studies have demonstrated that deep learning algorithms can achieve high levels of accuracy in blood cell classification. Convolutional neural networks trained on large datasets of labeled microscopic images have shown strong performance in distinguishing between different leukocyte subtypes and identifying abnormal cells associated with hematologic malignancies [5]. In some experimental settings, these models have achieved classification accuracies exceeding 90%, highlighting their potential as reliable tools for automated morphological screening.

Artificial intelligence systems have also demonstrated promising results in the detection of leukemic blast cells, which is a key diagnostic feature of acute leukemias. Accurate identification of blast cells is essential for early detection of diseases such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Deep learning models trained to recognize blast morphology have been shown to perform comparably to experienced hematologists in controlled validation studies [5]. By rapidly analyzing large numbers of cells within digital blood smear images, these systems may significantly accelerate the screening process and assist clinicians in identifying suspicious samples that require further diagnostic evaluation.

Similarly, AI-based approaches applied to bone marrow morphology have demonstrated encouraging diagnostic performance. Automated image analysis systems can classify hematopoietic cells and detect abnormal precursor populations associated with malignant disorders. In some studies, deep learning algorithms trained on annotated bone marrow datasets achieved diagnostic performance comparable to expert hematopathologists when distinguishing between normal and pathological cell populations [13,14].

Beyond simple classification tasks, artificial intelligence may also improve diagnostic reproducibility by reducing observer-dependent variability. Manual morphological evaluation can vary between observers, particularly in cases involving subtle cytological changes or borderline abnormalities. AI systems apply consistent analytical criteria across all analyzed samples, which may contribute to more standardized diagnostic assessments.

However, it is important to emphasize that the reported performance of AI models may vary depending on the quality and size of the training datasets used during model development. Many published studies rely on carefully curated image datasets obtained under controlled conditions, which may not fully reflect the variability encountered in routine clinical practice. Consequently, external validation across different laboratories and patient populations remains essential before these technologies can be widely implemented in hematology diagnostics.

3.2.4 Clinical Benefits and Practical Implications

The integration of artificial intelligence into hematological diagnostics offers several potential clinical benefits that may significantly improve laboratory efficiency and diagnostic workflows. One of the most important advantages of AI-based systems is their ability to rapidly analyze large numbers of cells and identify abnormal morphological patterns that may require further expert evaluation. Automated image analysis algorithms can process thousands of cells within a digital slide in a relatively short period of time, which may considerably reduce the time required for routine morphological screening.

In high-volume diagnostic laboratories, the increasing number of samples requiring microscopic evaluation represents a significant challenge for laboratory personnel. Artificial intelligence systems may assist laboratory specialists by performing preliminary screening of blood smear or bone marrow images and highlighting regions that contain suspicious or abnormal cells. By prioritizing cases that require detailed expert review, AI tools may help optimize laboratory workflows and allow specialists to focus on the most diagnostically challenging cases.

Another important benefit of AI-based diagnostic support systems is the potential improvement in diagnostic consistency. Traditional morphological evaluation may vary between observers due to differences in training, experience, and subjective interpretation of cellular features. Automated systems apply consistent analytical criteria to all analyzed samples, which may contribute to greater reproducibility and standardization of diagnostic assessments across different laboratories and institutions.

Artificial intelligence may also play an important role in improving access to hematological diagnostics in regions with limited medical resources. In many parts of the world, access to experienced hematologists or hematopathologists remains limited, particularly in rural or low-resource settings. AI-assisted diagnostic systems integrated with digital microscopy platforms could enable remote analysis of blood smear images and support clinicians in regions where specialized expertise is not readily available. Such technologies may facilitate telehematology approaches, allowing digital samples to be evaluated remotely by specialists or AI-assisted systems.

Despite these potential advantages, the implementation of artificial intelligence in routine clinical practice requires careful consideration of several practical and regulatory aspects. Issues related to data privacy, algorithm transparency, and regulatory approval must be addressed before AI-based systems can be fully integrated into clinical workflows. Furthermore, continuous monitoring and validation of algorithm performance are necessary to ensure that these systems maintain high diagnostic accuracy across diverse patient populations.

Overall, artificial intelligence should currently be viewed as a supportive technology designed to enhance, rather than replace, the expertise of trained hematologists and laboratory specialists. When properly implemented and validated, AI-based diagnostic tools have the potential to significantly improve efficiency, reproducibility, and accessibility of hematological diagnostics.

3.3 Artificial Intelligence in Flow Cytometry and Minimal Residual Disease Detection

3.3.1 Machine Learning in Flow Cytometry Data Analysis

Flow cytometry is widely regarded as one of the most powerful tools in modern hematology for the immunophenotypic characterization of hematopoietic cells. The ability to simultaneously measure multiple cellular parameters allows clinicians to identify abnormal cell populations and classify hematologic malignancies with high precision. However, the increasing complexity of multiparameter flow cytometry datasets has created significant challenges in data interpretation.

Modern flow cytometry experiments routinely generate measurements for hundreds of thousands to millions of individual cells across multiple fluorescence channels. Each cell is characterized by a multidimensional set of parameters representing the expression levels of specific surface or intracellular markers. Traditional analysis of these datasets relies on manual gating strategies in which experts define regions within multidimensional plots to identify specific cell populations [30]. While manual gating remains widely used in clinical practice, this approach may be time-consuming and may introduce subjectivity into the analysis process.

Machine learning techniques have therefore emerged as promising tools for automated analysis of flow cytometry data. These algorithms are capable of identifying patterns within high-dimensional datasets and detecting cellular populations based on complex combinations of marker expression. Unlike manual gating strategies, which rely on predefined thresholds, machine learning models can analyze the entire dataset simultaneously and identify subtle phenotypic differences between cell populations.

Several computational approaches have been proposed for the automated interpretation of flow cytometry data. Unsupervised learning methods such as clustering algorithms allow the identification of cell populations without prior labeling of training data. Techniques including self-organizing maps and dimensionality reduction algorithms have been successfully applied to visualize and interpret high-dimensional cytometry datasets [32,33]. These approaches can reveal phenotypic heterogeneity within cell populations and may help identify abnormal immunophenotypic signatures associated with hematologic malignancies.

Supervised machine learning models have also been used to classify disease states based on flow cytometry profiles. By training algorithms on datasets containing known diagnostic categories, these systems can learn to distinguish between normal and pathological cell populations. Several studies have demonstrated that machine learning models can accurately classify hematologic diseases based on immunophenotypic patterns observed in flow cytometry data [26,27].

The use of artificial intelligence in flow cytometry analysis may therefore improve both the efficiency and reproducibility of diagnostic workflows. Automated analysis tools can process large datasets rapidly and provide standardized interpretations of immunophenotypic patterns. These systems may assist clinicians in detecting abnormal cellular populations and identifying cases that require further investigation.

However, despite the promising results reported in research studies, the clinical adoption of machine learning tools for flow cytometry analysis remains limited. Challenges include the need for standardized datasets, validation of algorithms across different laboratory settings, and the development of transparent models that clinicians can interpret and trust. Consequently, most AI-based cytometry analysis systems are currently considered decision-support tools designed to assist, rather than replace, expert interpretation.

3.3.2 Artificial Intelligence in Minimal Residual Disease Detection

Minimal residual disease (MRD) refers to the presence of small numbers of malignant cells that remain in a patient after treatment and cannot be detected using conventional diagnostic methods such as standard microscopy. The detection of MRD has become a critical component of modern hematology, particularly in the management of acute leukemias and other hematologic malignancies. Numerous studies have demonstrated that the persistence of MRD is strongly associated with an increased risk of disease relapse and poorer overall prognosis.

Flow cytometry represents one of the most widely used techniques for MRD detection in clinical practice. By analyzing the expression patterns of multiple immunophenotypic markers, clinicians are able to identify rare malignant cells that may persist after therapy. However, MRD detection using conventional manual gating strategies can be extremely challenging due to the very low frequency of residual malignant cells, which may occur at levels as low as one malignant cell among tens of thousands of normal cells.

Artificial intelligence and machine learning techniques have therefore been increasingly investigated as potential tools for improving the sensitivity and reliability of MRD detection. Machine learning algorithms are capable of analyzing high-dimensional flow cytometry datasets and identifying abnormal immunophenotypic patterns that may indicate the presence of residual malignant cells. By processing large numbers of cellular events simultaneously, these algorithms may detect subtle deviations from normal immunophenotypic profiles that might be difficult to recognize using traditional manual analysis.

Several studies have demonstrated that machine learning–based approaches can improve the accuracy of MRD detection in hematologic malignancies. Algorithms trained on large cytometry datasets have shown promising results in identifying residual leukemic populations in patients with acute myeloid leukemia and acute lymphoblastic leukemia [21,23]. In some studies, machine learning models were able to detect abnormal cellular populations with sensitivity comparable to or exceeding that achieved through manual gating performed by experienced cytometrists.

In addition to improving diagnostic sensitivity, AI-based approaches may also enhance the reproducibility of MRD analysis. Traditional MRD assessment may vary between laboratories depending on gating strategies and analytical approaches. Automated algorithms apply consistent criteria to all analyzed samples, which may reduce inter-laboratory variability and contribute to more standardized MRD evaluation.

Despite these promising developments, the implementation of AI-assisted MRD detection in routine clinical practice remains an evolving field. The reliability of machine learning models depends heavily on the availability of large, well-annotated training datasets and careful validation across diverse patient populations. Furthermore, integration of these tools into existing laboratory workflows requires collaboration between clinicians, bioinformaticians, and regulatory bodies to ensure safe and effective clinical application.

3.3.3 Challenges and Limitations of Artificial Intelligence in Flow Cytometry

Despite the considerable potential of artificial intelligence in the analysis of flow cytometry data, several challenges must be addressed before these technologies can be widely adopted in routine clinical practice. One of the most important issues concerns the availability and quality of training datasets required for the development of reliable machine learning models. Flow cytometry datasets used for algorithm training must contain accurately labeled cellular populations and represent the full spectrum of phenotypic variability encountered in clinical hematology. However, the generation of such datasets requires extensive expert annotation, which can be both time-consuming and resource-intensive.

Another important challenge relates to the standardization of flow cytometry data across different laboratories. Variations in instrument configuration, antibody panels, staining protocols, and data acquisition settings may significantly influence the resulting datasets. Machine learning models trained on data generated in one laboratory may therefore perform less effectively when applied to data obtained from different institutions. This lack of standardization represents a major obstacle for the generalization of AI-based cytometry analysis systems.

Interpretability of artificial intelligence models is also an important consideration in clinical diagnostics. Many machine learning approaches, particularly deep learning algorithms, function as complex computational models whose internal decision-making processes may not be easily interpretable by clinicians. In medical settings, diagnostic decisions must often be transparent and explainable, especially when they may influence treatment strategies or patient outcomes. As a result, the development of interpretable AI systems that provide clear explanations for their predictions remains an active area of research.

Data privacy and regulatory considerations also play an important role in the clinical implementation of AI-based diagnostic tools. Flow cytometry datasets are typically derived from patient samples and therefore contain sensitive medical information. The development and deployment of machine learning models must comply with strict data protection regulations and ethical guidelines governing the use of patient data in medical research and clinical applications.

Finally, integration of AI-based analysis tools into existing laboratory workflows represents an additional practical challenge. Clinical laboratories rely on established diagnostic protocols and information systems, and the introduction of new computational tools requires careful validation and compatibility with existing infrastructure. For these reasons, most experts currently view artificial intelligence as a complementary technology designed to assist laboratory specialists rather than replace expert interpretation of flow cytometry data.

3.4 Artificial Intelligence in Prognostic Modeling and Clinical Decision Support

3.4.1 Machine Learning Models for Risk Stratification in Hematologic Malignancies

Accurate risk stratification is a fundamental aspect of clinical management in hematologic malignancies. Prognostic assessment allows clinicians to estimate disease progression, determine the likelihood of treatment response, and select appropriate therapeutic strategies for individual patients. Traditional prognostic models in hematology are typically based on a limited number of clinical, laboratory, and genetic parameters, such as cytogenetic abnormalities, molecular mutations, and hematologic indices. Although these models have significantly improved patient management, they may not fully capture the complex biological interactions underlying disease progression.

In recent years, artificial intelligence and machine learning approaches have emerged as promising tools for improving prognostic modeling in hematology. Machine learning algorithms are capable of analyzing large and complex datasets that integrate multiple types of clinical information, including laboratory results, genomic data, imaging findings, and patient characteristics. By identifying patterns within these multidimensional datasets, AI models can generate predictive models that may outperform traditional statistical approaches in certain clinical scenarios.

Several studies have explored the use of machine learning techniques for risk stratification in hematologic malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. These models are often trained using large clinical datasets containing information on patient demographics, laboratory values, cytogenetic abnormalities, and molecular mutations. By analyzing these variables simultaneously, machine learning algorithms can identify combinations of prognostic factors that may not be apparent using conventional analytical methods.

In the context of acute myeloid leukemia, for example, machine learning models have been used to predict overall survival and treatment outcomes based on integrated clinical and genomic data. These models

may assist clinicians in identifying high-risk patients who could benefit from more aggressive therapeutic strategies or early consideration of hematopoietic stem cell transplantation. Similarly, AI-based models have been applied to predict disease progression in myelodysplastic syndromes and to improve prognostic classification beyond existing scoring systems.

Another important advantage of AI-based prognostic models is their ability to continuously incorporate new data and adapt to evolving clinical knowledge. As additional patient data become available, machine learning systems can update their predictive models and refine risk stratification algorithms. This dynamic learning capability may contribute to the development of more personalized treatment strategies in hematologic oncology.

Despite these promising applications, several challenges remain in the clinical implementation of AI-driven prognostic models. The reliability of predictive algorithms depends heavily on the quality and completeness of the datasets used for training. In addition, external validation across independent patient cohorts is essential to ensure that these models maintain their predictive accuracy in diverse clinical settings. Therefore, while artificial intelligence holds considerable promise for improving prognostic assessment in hematology, further research is required to establish its role in routine clinical decision-making.

3.4.2 Artificial Intelligence in Treatment Response Prediction

Predicting treatment response is a critical component of personalized medicine in hematologic malignancies. Patients diagnosed with diseases such as acute leukemia, lymphoma, or multiple myeloma often exhibit significant variability in their response to therapy. While some patients achieve long-term remission, others may demonstrate resistance to treatment or experience early disease relapse. Identifying patients who are likely to respond to specific therapeutic strategies remains a major challenge in clinical hematology.

Artificial intelligence and machine learning models have increasingly been investigated as tools for predicting treatment outcomes based on complex clinical and molecular datasets. Unlike traditional statistical models that rely on a limited number of predefined variables, machine learning algorithms can integrate large amounts of heterogeneous data, including genomic profiles, laboratory parameters, imaging findings, and clinical characteristics. By analyzing these multidimensional datasets, AI systems may identify patterns associated with treatment sensitivity or resistance.

Several studies have explored the use of machine learning models to predict response to chemotherapy and targeted therapies in hematologic malignancies. In acute myeloid leukemia, for example, predictive models have been developed to estimate the probability of complete remission following induction chemotherapy by incorporating genetic mutations, cytogenetic abnormalities, and clinical parameters into machine learning algorithms. These models may assist clinicians in identifying patients who are unlikely to benefit from standard treatment approaches and who may require alternative therapeutic strategies.

Artificial intelligence has also been applied to predict responses to targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibody-based treatments. By integrating genomic and molecular information, AI models may help identify patients whose tumors harbor specific molecular alterations associated with sensitivity to particular drugs. This approach may contribute to more precise selection of therapeutic agents and improve treatment outcomes.

Another promising area of research involves the use of machine learning algorithms to predict treatment-related complications and adverse events. By analyzing large clinical datasets, AI models may identify risk factors associated with severe toxicity or treatment intolerance. Such predictive tools could help clinicians tailor treatment intensity and improve patient safety during therapy.

Despite these promising developments, the integration of AI-based treatment response prediction into routine clinical practice remains limited. Many predictive models have been developed using retrospective datasets and require prospective validation before they can be reliably applied in clinical decision-making. Furthermore, the interpretability of predictive models and their integration with existing clinical workflows remain important considerations for future research.

3.4.3 Artificial Intelligence–Based Clinical Decision Support Systems

Clinical decision support systems (CDSS) represent an important application of artificial intelligence in modern medicine. These systems are designed to assist clinicians in making diagnostic and therapeutic decisions by analyzing large amounts of clinical data and providing evidence-based recommendations. In hematology, where diagnostic and therapeutic decisions often require the integration of complex clinical, laboratory, and molecular information, AI-based decision support systems may play a particularly valuable role.

The management of hematologic malignancies typically involves the evaluation of multiple diagnostic parameters, including peripheral blood morphology, bone marrow findings, immunophenotypic profiles obtained through flow cytometry, cytogenetic abnormalities, and molecular genetic alterations. Interpreting these diverse data sources and translating them into optimal treatment strategies can be challenging, especially in cases involving rare diseases or complex genomic profiles.

Artificial intelligence systems have the potential to assist clinicians by integrating these diverse data sources and generating predictive insights that may support clinical decision-making. Machine learning algorithms can analyze patient-specific datasets and compare them with large clinical databases to identify patterns associated with favorable or unfavorable treatment outcomes. Such systems may provide recommendations regarding risk stratification, treatment selection, and monitoring strategies.

AI-based clinical decision support tools may also facilitate the implementation of precision medicine in hematology. By integrating genomic and molecular data with clinical parameters, these systems can help identify patient subgroups that may benefit from targeted therapies or individualized treatment strategies. This approach may contribute to improved therapeutic outcomes and reduced treatment-related toxicity.

Despite their potential benefits, AI-driven decision support systems must be carefully validated before they can be incorporated into routine clinical practice. Clinical decision-making in hematology involves complex ethical and medical considerations, and automated recommendations must always be interpreted within the broader clinical context. Therefore, AI-based decision support systems should be viewed as tools that augment clinical expertise rather than replace physician judgment.

3.5 Limitations and Challenges of Artificial Intelligence in Hematology

The rapid development of artificial intelligence has generated significant interest in its potential applications within hematology. Although numerous studies have demonstrated promising results in areas such as automated cell classification, flow cytometry analysis, and prognostic modeling, several important limitations must be addressed before AI-based systems can be widely integrated into routine clinical practice.

One of the primary challenges associated with artificial intelligence in hematology is the availability and quality of training data. Machine learning models require large, well-annotated datasets in order to achieve reliable performance. In the context of hematologic diagnostics, generating such datasets often requires extensive manual annotation performed by experienced hematologists or hematopathologists. This process can be extremely time-consuming and may limit the availability of sufficiently large training datasets, particularly for rare hematologic disorders.

Another important issue concerns the representativeness of available datasets. Many AI models are trained using data obtained from a limited number of institutions, which may not fully reflect the diversity of patient populations, laboratory techniques, and imaging conditions encountered in routine clinical practice. Differences in staining protocols, microscope configurations, or flow cytometry instrumentation may influence the characteristics of diagnostic data. As a result, models trained under specific conditions may demonstrate reduced performance when applied to data from different clinical environments.

Algorithm interpretability represents an additional challenge in the clinical application of artificial intelligence. Many modern AI systems, particularly deep learning models, function as highly complex computational structures whose internal decision-making processes may not be easily interpretable. In medical practice, however, clinicians often require transparent explanations for diagnostic recommendations, especially when these decisions may influence treatment strategies or patient outcomes. The development of interpretable and explainable AI models therefore remains an important research priority.

Data privacy and regulatory considerations also play a critical role in the implementation of AI-based diagnostic tools. Clinical datasets used to train machine learning models often contain sensitive patient information and must therefore comply with strict data protection regulations. Ensuring secure data storage, anonymization, and ethical use of patient data is essential for maintaining public trust and regulatory approval of AI technologies in healthcare.

In addition to technical and regulatory challenges, practical issues related to clinical implementation must also be considered. Integrating AI-based tools into existing laboratory workflows requires compatibility with laboratory information systems, standardized data formats, and appropriate user interfaces that allow clinicians to interpret algorithm outputs effectively. Without careful integration into clinical practice, even highly accurate AI systems may fail to achieve widespread adoption.

Another concern relates to potential bias in machine learning models. If training datasets are not sufficiently diverse, algorithms may learn patterns that are specific to particular patient populations or clinical

settings. This may lead to reduced diagnostic accuracy when the model is applied to different populations. Addressing such biases requires the development of large multicenter datasets and extensive external validation of AI models across diverse clinical environments.

Finally, it is important to recognize that artificial intelligence should not be viewed as a replacement for clinical expertise. Hematological diagnostics often require the integration of multiple sources of information, including clinical history, laboratory results, imaging findings, and physician judgment. AI-based systems may serve as valuable decision-support tools, but the final diagnostic interpretation must remain under the responsibility of trained medical professionals.

4. Discussion: Future Perspectives of Artificial Intelligence in Hematology

Artificial intelligence is expected to play an increasingly important role in the future of hematological diagnostics and clinical management. Rapid advances in computational methods, digital imaging technologies, and genomic sequencing are creating new opportunities for the development of integrated diagnostic systems capable of analyzing complex biomedical data. As these technologies continue to evolve, artificial intelligence may significantly transform the way hematologic diseases are diagnosed, classified, and treated.

One of the most promising future directions in hematology is the integration of multimodal data analysis. Modern diagnostic evaluation of hematologic malignancies often involves multiple sources of information, including morphological examination of peripheral blood and bone marrow, immunophenotypic data obtained through flow cytometry, cytogenetic abnormalities, and molecular genetic findings. Artificial intelligence systems capable of integrating these diverse data types may provide more comprehensive insights into disease biology and improve diagnostic accuracy.

Another important area of development involves the expansion of digital pathology platforms. The increasing adoption of whole-slide imaging technologies allows microscopic specimens to be digitized and analyzed using advanced computational tools. In the future, AI-based image analysis systems may become an integral part of digital hematopathology workflows, enabling automated screening of bone marrow and peripheral blood specimens and assisting pathologists in identifying diagnostically relevant morphological features.

Advances in genomic sequencing technologies are also likely to further enhance the role of artificial intelligence in hematology. The widespread use of next-generation sequencing has generated large volumes of genomic data that require sophisticated analytical methods for interpretation. Machine learning algorithms may help identify complex interactions between genetic mutations and clinical outcomes, thereby improving prognostic models and supporting the development of personalized therapeutic strategies.

Another promising research direction involves the development of federated learning approaches for medical artificial intelligence. Federated learning enables machine learning models to be trained on datasets from multiple institutions without requiring direct sharing of sensitive patient data. This approach may facilitate the creation of large multicenter datasets while maintaining strict data privacy standards, thereby improving the generalizability and robustness of AI models in hematology.

Artificial intelligence may also play a growing role in clinical workflow optimization and telemedicine applications. In regions with limited access to specialized hematology expertise, AI-assisted diagnostic systems integrated with digital microscopy platforms could support remote evaluation of blood smears and bone marrow specimens. Such technologies may help reduce disparities in access to high-quality hematologic diagnostics and improve patient care in resource-limited settings.

Despite these promising developments, the successful implementation of artificial intelligence in hematology will require close collaboration between clinicians, researchers, data scientists, and regulatory authorities. Establishing standardized datasets, validating algorithms across diverse clinical environments, and developing transparent and interpretable AI models will be essential for ensuring safe and effective clinical use of these technologies.

Overall, the continued development of artificial intelligence has the potential to significantly enhance diagnostic precision, improve prognostic assessment, and support more personalized treatment strategies in hematologic diseases. As research in this field progresses, AI-based tools may become an integral component of modern hematology practice.

5. Conclusions

Artificial intelligence has emerged as a rapidly developing field with significant potential to transform multiple aspects of hematological diagnostics and clinical management. Advances in machine learning, deep learning, and digital pathology have enabled the development of computational tools capable of analyzing complex biomedical data derived from peripheral blood morphology, bone marrow examinations, flow cytometry, and molecular diagnostics.

As discussed throughout this review, artificial intelligence systems have demonstrated promising performance in several areas of hematology. Deep learning models have shown high accuracy in automated classification of blood cells and detection of leukemic blast cells in peripheral blood smear images. Similarly, machine learning approaches applied to flow cytometry data have improved the identification of abnormal immunophenotypic populations and enhanced the detection of minimal residual disease. In addition, AI-based prognostic models have demonstrated potential in predicting disease progression, treatment response, and clinical outcomes in patients with hematologic malignancies.

Despite these promising developments, several important challenges must still be addressed before artificial intelligence can be widely implemented in routine clinical practice. Issues related to data quality, model generalizability, algorithm interpretability, and regulatory oversight remain important considerations. Furthermore, the successful integration of AI-based tools into clinical workflows requires careful validation and collaboration between clinicians, data scientists, and regulatory authorities.

Importantly, artificial intelligence should be viewed as a supportive technology that enhances, rather than replaces, the expertise of hematologists and laboratory specialists. The interpretation of diagnostic findings and the management of complex hematologic diseases require comprehensive clinical judgment that cannot be fully replicated by automated systems.

In the coming years, continued advances in digital pathology, genomic analysis, and multimodal data integration are likely to further expand the role of artificial intelligence in hematology. With appropriate validation and responsible implementation, AI-based technologies may contribute to improved diagnostic accuracy, more personalized treatment strategies, and ultimately better outcomes for patients with hematologic diseases.

REFERENCES

1. Nazha, A., Elemento, O., Ahuja, S., Lam, B., Miles, M., Shouval, R., et al. (2025). Artificial intelligence in hematology. *Blood, 146*(19), 2283–2292. https://doi.org/10.1182/blood.2025029876
2. Schnegg-Kaufmann, A. S., Bacher, U., Rovó, A., Andres, M., Wiedemann, G., Porret, N., Moshaver, B., Kaufmann, N., Tchinda, J., Meyer, S. C., & Angelillo-Scherrer, A. (2025). Artificial intelligence in haematologic diagnostics: Current applications and future perspectives. *Acta Haematologica*, 1–14. https://doi.org/10.1159/000548753
3. Walter, W., Pohlkamp, C., Meggendorfer, M., Nadarajah, N., Kern, W., Haferlach, C., & Haferlach, T. (2023). Artificial intelligence in hematological diagnostics: Game changer or gadget? *Blood Reviews, 58*, 101019. https://doi.org/10.1016/j.blre.2022.101019
4. El Alaoui, Y., Elomri, A., Qaraqe, M., Padmanabhan, R., Taha, R. Y., El Omri, H., El Omri, A., & Aboumarzouk, O. (2022). A review of artificial intelligence applications in hematology management: Current practices and future prospects. *Journal of Medical Internet Research, 24*(7), e36490. https://doi.org/10.2196/36490
5. Lin, E., & Chen, M. (2023). Digital pathology and artificial intelligence as the next frontier in hematolymphoid disease. *[Review]*. PMID: 36801182.
6. Lewis, J. E., & Pozdnyakova, O. (2023). Digital assessment of peripheral blood and bone marrow aspirate smears. *International Journal of Laboratory Hematology, 45*(Suppl. 2), 50–58. https://doi.org/10.1111/ijlh.14082
7. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
8. Boldú, L., et al. (2021). A deep learning model (ALNet) for the diagnosis of acute leukaemia lineage using peripheral blood cell images. *Computer Methods and Programs in Biomedicine, 202*, 105999. PMID: 33618145.
9. Kasim, S., Malek, S., Tang, J., Kiew, X. N., Cheen, S., Liew, B., et al. (2025). Multiclass leukemia cell classification using hybrid deep learning and machine learning with CNN-based feature extraction. *Scientific Reports, 15*(1), 23782. PMID: 40610551.
10. Islam, M. M., et al. (2024). Utilizing deep feature fusion for automatic leukemia detection from peripheral blood smear images. PMID: 39001200.
11. Aby, A. E., et al. (2025). Classification of acute myeloid leukemia by pre-trained convolutional neural networks using peripheral blood smear images. PMID: 39922655.

12. Rastogi, P., et al. (2022). LeuFeatx: Deep learning-based feature extractor for leukocyte classification using microscopic images. PMID: 35066445.
13. Sun, S., et al. (2025). DeepHeme, a high-performance, generalizable deep learning approach for bone marrow cell morphology classification. PMID: 40498857.
14. Saft, L., et al. (2025). A deep-learning algorithm (AIFORIA) for classification of hematopoietic cells in bone marrow aspirate smears based on nine cell classes. *Journal of Hematopathology, 18*(1), 12. PMID: 40156646.
15. Su, J., et al. (2024). A cell detection and confirmation network of bone marrow aspirate images for aided diagnosis of AML (CDC-NET). PMID: 37953336.
16. Mu, Y., et al. (2023). Whole slide image representation in bone marrow cytology with deep learning. PMID: 37837726.
17. Dehkharghanian, T., et al. (2023). A novel visualization of bone marrow aspirate cytology (cell projection plots) toward clinically relevant AI support. PMID: 37732298.
18. Chen, P., et al. (2021). Detection of metastatic tumor cells in the bone marrow aspirate smears using a deep learning system (Morphogo). PMID: 34646779.
19. Ko, B. S., et al. (2018). Clinically validated machine learning algorithm for automated flow cytometric MRD assessment in AML/MDS. PMID: 30361063.
20. Li, J. L., et al. (2019). Learning a cytometric deep phenotype embedding for automatic MRD classification. PMID: 31946232.
21. Reiter, M., et al. (2019). Automated flow cytometric MRD assessment in childhood B-ALL using supervised machine learning. *Cytometry Part A*. PMID: 31282025.
22. Weijler, L., et al. (2022). UMAP based anomaly detection for minimal residual disease in leukemia flow cytometry. PMID: 35205645.
23. Shopsowitz, K., et al. (2024). MAGIC-DR: An interpretable machine-learning guided approach for AML MRD analysis. PMID: 38415807.
24. Shopsowitz, K. E., et al. (2022). Machine learning optimized multiparameter radar plots for B-ALL MRD discrimination. PMID: 35726954.
25. Wödlinger, M., et al. (2022). Automated identification of cell populations in flow cytometry using transformer-based neural networks. PMID: 35247762.
26. Ji, D., et al. (2020). Machine learning of discriminative gate locations for clinical cytometry diagnosis. PMID: 31691488.
27. Wang, Y. F., et al. (2024). Using artificial intelligence to interpret clinical flow cytometry datasets for disease classification and residual disease monitoring. PMID: 38526794.
28. Ng, D. P., et al. (2021). Augmented human intelligence and automated diagnosis of B-cell malignancies from clinical flow cytometry. PMID: 33210119.
29. Mallesh, N., et al. (2021). Knowledge transfer (transfer learning) to enhance performance of deep models for clinical flow cytometry across panels. PMID: 34693376.
30. Scheuermann, R. H., et al. (2017). Automated analysis of clinical flow cytometry data. *Clinics in Laboratory Medicine*. PMID: 29128077.
31. Finak, G., et al. (2016). Standardizing flow cytometry immunophenotyping analysis: Automated gating can match centralized manual analysis. PMID: 26861911.
32. Van Gassen, S., et al. (2015). FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry Part A, 87*(7), 636–645. PMID: 25573116.
33. Amir, E. D., et al. (2013). viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nature Biotechnology, 31*(6), 545–552. PMID: 23685480.
34. Lo, K., Hahne, F., Brinkman, R. R., & Gottardo, R. (2009). flowClust: A Bioconductor package for automated gating of flow cytometry data. *BMC Bioinformatics, 10*, 145. PMID: 19442304.
35. Quintelier, K., et al. (2021). Analyzing high-dimensional cytometry data using FlowSOM. *Nature Protocols*. PMID: 34172973.
36. Spies, N. C., Rangel, A., English, P., Morrison, M., O'Fallon, B., & Ng, D. P. (2025). Machine learning methods in clinical flow cytometry. *Cancers, 17*(3), 483. PMID: 39941850.